Stockscreener 앱 받기
8.64
5.68%
-0.52
시간 외 거래:
8.64
전일 마감가:
$9.16
열려 있는:
$9.24
하루 거래량:
170.70K
Relative Volume:
1.31
시가총액:
$45.92M
수익:
$7.97M
순이익/손실:
$-75.74M
주가수익비율:
-0.3558
EPS:
-24.2853
순현금흐름:
$-85.33M
1주 성능:
-0.58%
1개월 성능:
+14.44%
6개월 성능:
-74.43%
1년 성능:
-31.39%
1일 변동 폭
$8.64
$9.92
1주일 범위
$8.20
$9.92
52주 변동 폭
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
명칭
Aligos Therapeutics Inc
전화
(800) 466-6059
주소
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
ALGS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
8.64 | 53.14M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
| 2023-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-01-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-09 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 재개 | Piper Sandler | Overweight |
| 2020-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 개시 | JP Morgan | Overweight |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Is Aligos Therapeutics Inc. a good long term investmentTurbocharged investment results - jammulinksnews.com
Aligos Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - jammulinksnews.com
What analysts say about Aligos Therapeutics Inc. stockAccelerated investment success - jammulinksnews.com
What drives Aligos Therapeutics Inc. stock priceExtraordinary performance - jammulinksnews.com
Why Aligos Therapeutics Inc. stock attracts strong analyst attentionFree Investing Community - Newser
How Aligos Therapeutics Inc. stock performs during market volatilityVerified Return Tips - Newser
What makes Aligos Therapeutics Inc. stock price move sharplyTop Momentum Stock Pick - Newser
Aligos Therapeutics (ALGS) Grants Stock Options to New Employees - GuruFocus
Aligos Therapeutics Grants 2,100 Shares in Stock Options to New Hires with 4-Year Vesting Terms - Stock Titan
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
(ALGS) Investment Analysis and Advice - news.stocktradersdaily.com
Aligos Therapeutics Approves Major Amendments at Annual Meeting - TipRanks
Is Aligos Therapeutics, Inc. technically bullish or bearish? - MarketsMojo
How To Trade (ALGS) - news.stocktradersdaily.com
Aligos Therapeutics (ALGS) Welcomes New VP of Chemistry Manufacturing Controls | ALGS Stock News - GuruFocus
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing - Bluefield Daily Telegraph
Aligos Therapeutics Strengthens Drug Development Team: Former Kezar Executive to Drive Phase 2 Trial Progress - Stock Titan
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC) - Yahoo Finance
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Aligos Therapeutics (ALGS) Issues Stock Options to New Employees | ALGS Stock News - GuruFocus
Aligos Therapeutics Awards Major Stock Options Package: New Employees Get 26,000 Shares Under Nasdaq Rule - Stock Titan
(ALGS) Long Term Investment Analysis - news.stocktradersdaily.com
5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Decline in Short Interest - Defense World
Clinical Stage Liver Disease Biotech Aligos Set for Major Jefferies Conference Presentation - Stock Titan
How the (ALGS) price action is used to our Advantage - news.stocktradersdaily.com
Financial Comparison: Entera Bio (NASDAQ:ENTX) versus Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (ALGS) Appoints New Head of Legal | ALGS Stock News - GuruFocus
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal - The Manila Times
Former Genentech and Codexis Legal Leader Takes Top Legal Role at Liver Disease Biotech Aligos - Stock Titan
Aligos Therapeutics Issues 26,000-Share Inducement Grant To New Employee - Nasdaq
Aligos Therapeutics (ALGS) Awards New Employee Stock Option Gran - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ALGS Stock News - GuruFocus
Aligos Therapeutics (ALGS) Awards New Employee Stock Option Grant | ALGS Stock News - GuruFocus
Aligos Therapeutics Expands Liver Disease Team with Strategic Hire, Awards 26,000 Share Options - Stock Titan
Pre-market Movers: IXHL, KLRS, HCTI, DOCS... - RTTNews
Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations - Yahoo Finance
Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation - simplywall.st
Aligos reports promising HBV treatment data at EASL Congress - Investing.com
Aligos Therapeutics (ALGS) Showcases Promising HBV Treatment Results at EASL Congress 2025 | ALGS Stock News - GuruFocus
Aligos reports promising HBV treatment data at EASL Congress By Investing.com - Investing.com Nigeria
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 - The Manila Times
Aligos Therapeutics Inc (ALGS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):